RDIF, Panacea Biotec partner to produce Sputnik V in India
First batch produced at Panacea Biotec s facilities at Baddi will be shipped to the Gamaleya Centre for quality control. Full-scale production of the vaccine is due to start soon
BusinessToday.In | May 24, 2021 | Updated 16:22 IST
Sputnik V vaccine got the emergency use authorisation in the country on April 12
Russia s sovereign wealth fund RDIF (Russian Direct Investment Fund) and homegrown pharma company Panacea Biotec have partnered to launch the Russian Sputnik V vaccine in India. The RDIF has already tied up with Dr Reddy s to produce the vaccine in India. Both have agreed to produce 100 million doses per year of Sputnik V.
UPDATED: May 25, 2021 05:10 IST
Sputnik V was given emergency use authorisation by the Indian government on April 12 this year. (Photo: Reuters)
The Russian Direct Investment Fund (RDIF) has started the production of Sputnik V Covid-19 vaccine in India in collaboration with domestic pharma major Panacea Biotec. The joint venture is going to produce 100 million doses per year of Sputnik V in India and is expected to undergo full-scale production this summer, a joint statement issued on Monday said.
RDIF, a Russian sovereign wealth fund that markets the vaccine internationally, in April had announced a collaboration with Panacea Biotec. The first batch of the vaccine will be produced at Panacea Biotec s facilities at Baddi in Himachal Pradesh. This batch will then be shipped to Russia s Gamaleya Center for quality control , the joint statement said.
India will produce a total of 850 million doses of the Sputnik V vaccine and production will start in August. Russia has already sent two batches of the Sputnik V vaccine to India.